Research shows Flavay® binds to collagen fibers and realigns them to a more youthful, undamaged form.

Smoother Skin from Within Flavay Promotes Collagen Production, Inhibits Elastin Degradation and Reduces Inflammation

"[A] method for preventing and fighting the harmful biological effects of free radicals...namely...inflammation...[and] collagen degradation"

Flavay® can have a dramatic, visible effect on your skin. The nutrients in Flavay® can be considered as 'collagen vitamins' because they partake in the biosynthesis of collagen and prevent its destruction. Through synergistic action with vitamin C, Flavay® strengthens and rebuilds the body’s natural collagen proteins and has the remarkable ability to reactivate damaged collagen and elastin. Research has demonstrated that Flavay® binds to collagen fibers and realigns them to a more youthful, undamaged form. (The same research also established that common bioflavonoids are completely inactive in this respect.)

Laboratory tests have demonstrated Flavay’s® ability to reduce degradation of elastin fibers by up to 70 percent.

Flavay® improves the beneficial cross-linking between the amino acids of the fibers that give skin its flexibility and strength while preventing the undesirable cross-linking between amino acids that ages skin like leather. Laboratory tests have demonstrated Flavay’s™ ability to reduce degradation of elastin fibers by up to 70 percent.

Flavay’s® ability to reactivate damaged collagen and elastin has great implications for all of your body’s organs. Collagen is required for the normal functioning of the joints, healthy cartilage and bones, smooth gliding surfaces, synovial fluid, normal joint spaces and normal soft tissues surrounding the joints. Collagen is the building block of connective tissue, veins, arteries, ligaments and tendons, and every tissue and organ.

Flavay® Improves Circulation to Skin Cells

Flavay® strengthens collagen in vessel walls and capillaries— resulting in radiant and more youthful skin.

Improved circulation is another reason that Flavay® is an important part of optimally nourishing your skin. Over 60 years of scientific and clinical research establishes that Flavay® actually strengthens collagen in vascular walls and capillaries (the smallest vessels) by making the vessels stronger and more elastic. As we age, the tiny capillaries begin to break down, resulting in diminished blood flow. Fortifying these tiny blood vessels will improve circulation throughout the body, including the skin, delivering blood and nutrients to your skin. Improved circulation results in well-nourished, healthy skin—which is radiant and more youthful.

Inflammations and Edema (Swelling)

Flavay® has been licensed and sold in France for treating edema and inflammations since 1950. Puffiness of the eyes and an overall bloated look and feel are examples of edema. It involves the leakage of blood serum into surrounding tissues and Flavay® has shown that it can reduce this leakage by strengthening capillary walls.

Flavay® inhibits the release and synthesis of histamine—a key factor in the promotion of inflammation.

One of the very first benefits observed and studied by the inventor of Flavay®, Dr. Jack Masquelier, in as early as 1947, was its anti-inflammatory effect. His and others' research demonstrated that Flavay® inhibits the release and synthesis of histamine (which produces accelerated blood flow, dilates capillaries and increases their permeability, thereby leaking plasma into surrounding tissue), a key factor in the promotion of inflammation. Numerous studies have demonstrated that the anti-histamine action of Flavay® is obtained through inhibiting the activity of the enzyme histidine decarboxylase. Research shows that Flavay® may lower the production of histamine with as much as 86% inhibition of histidine decarboxylase.

In an Australian study conducted on two groups of soccer players that had sustained injuries, those that consumed Flavay® for ten days following their injuries experienced significantly less swelling than those who did not and, in some of those taking Flavay®, the swelling had completely disappeared. Other research has demonstrated the ways in which Flavay® may actually inhibit inflammation including double-blind studies conducted in France which showed that Flavay® can reduce postoperative inflammation.

Proven Safety of Flavay®

After more than 60 years of human use, no adverse effects have been observed. Furthermore, intensive biological, toxicological, pharmacological and analytical research was conducted for the purpose of registering it as a medicine in France and other countries in Europe. In one study, daily doses of up to 35,000 mg for six months were determined to cause no adverse effects. Flavay® was also clinically tested, in particular for all sorts of symptoms related to venolymphatic insufficiencies (strenghthening veins, improving circulation and reducing edema and inflammations). The spin-off is a goldmine of data: The rigorous testing to meet the standards required by the health ministries of France, Germany and other European countries demonstrate that Flavay® is highly bioavailable, nontoxic, nonallergenic, noncarcinogenic, nonmutagenic, will not cause birth defects, and is completely safe.

Dr. Masquelier’s unequaled manufacturing process has been conducted for half a century at the very same facilities in France, and under the control of French Pharmaceutical inspection. These time-proven standards serve as a reliable assurance of the quality, consistency, bioavailability and safety of Flavay®.

Who can take Flavay®?

Everyone, from the very young to elderly. Flavay® has no known contraindications (conditions under which it should not be used). Flavay® is completely safe and nontoxic. In fact, clinical trials have been conducted in which pregnant women (troubled by varicose veins and other circulatory problems in the legs) safely used Flavay®.

Why Trust Flavay®

Consumers need to know that the marketplace is full of imitations, various “extracts” and derivative forms of Dr. Masquelier’s scientifically proven and pefected complex. Unfortunately, many have even used Dr. Masquelier’s name and research in unauthorized ways to promote illegitimate products.

Flavay® is the name you can trust for the precisely defined active polyphenol complex proven and perfected by the inventor, Dr. Jack Masquelier, validated by the French Ministry of Health and documented by a library of research consisting of many patents and hundreds of scientific papers, articles, doctorate theses, lectures and presentations. For quality, consistency, bioavailability and safety, consumers may rely upon Flavay®.

Flavay® Improves the Health and Appearance of Skin

Flavay® is the amazing internal cosmetic, improving the health and appearance of the skin from the inside out: rebuilding collagen, improving circulation and health in skin cells, and reducing inflammation.


Buy Flavay Now

for a healthy mind & body
* Statements made herein have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
NOTE: We do not compensate for our endorsements and testimonials. We do not consider paid testimonials to be nearly as valuable as comments from customers who were not compensated and yet liked the products so much they gave their testimonials anyway.
Masquelier, J. A lifetime devoted to OPC and [pyc]. Alfa Omega Editrice, Pub., 1996. Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice, Publishers, 1995. Kilham, C., Masquelier, J. OPC: The miracle antioxidant. Keats Publishing, Inc., 1997. Mindell, E., et al. Earl Mindell’s vitamin bible for the 21st century. Warner Books, Inc., 1999. Passwater, R.A. The antioxidants: the nutrients that guard your body. Keats Publishing, Inc., 1985. Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants. Keats Publishing, Inc., 1995. Facino RM, et al. Free radical scavenging action and anti-enzyme activities of procyanidines from Vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994. Kuttan R, et al. Collagen treated with catechin becomes resistant to the action of mammalian collagenase. Experientia, 37: 221-223, 1981. Masquelier, J., et al. Stabilization du collagene par les oligomeres procyanidoliques. Acta Therapeutica, 7:101-105, 1981. Masquelier, J. Aspects pharmacologiques nouveaux de certains flavonoides. A Vie Medical 12:1969. Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques totaux du raisin. Acta Therapeutica, 4, 1978. Laparra, J., et al. Etude pharmacocinetique des oligomeres flavonoliques. Plantes med et phyto, Tome XI, pp. 133-142, 1977. Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de l’action des oligomeres procyanidoliques sur des cellules mesenchymateuses en culture. Ii l’attachment des fibres elastiques aux cellules. (Study of the effect of procyanidolic oligomers on mesenchymal cells in culture. Ii attachment of elastic fibers to the cells.) Pat Biol, (30)6:601-7, 1990. Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular and crystal structure of (+)-2,3-trans-3,4-trans-leucocyanidin [(2r,3s,+r)-(+)-3,3’, 4.4’, 5.7’-Hexahydroxyflavan] dihydrate, and comparison of its heterocyclic ring conformation in solution and the solid state. Journal of the Chemical Society; Perkin Transactions I 1985. pp. 1413-17. Masquelier, J. Proanthocyanidins et radicaux libres. 1985. Uchida, S., et al. Condensed tannins scavenge active oxygen free radicals. Med Sci Res, (15) 1987. pp. 831-832. Ariga, T. Radical scavenging action and its mode in procyanidins b-1 and b-3 from azuki beans to peroxyl radicals. Agric Biol Chem, 54(10) 1990. pp. 2499-2504. Da Silva, R., et. al. Radical scavenger capacity of different procyanidins from grape seeds. Presented at a symposium, “Free radicals in biotechnology and medicine.” Royal Society Of Chemistry, London January 1990, pp. 79-80. Bauman, J., Wurm, G., Bruchhausen, F. “Hemmung der prostagladinsynthetase durch flavonoide und phenolderivate im vergleich nit deren 02 radikalfangereigenschaften” Arch Pharm, (Weinheim) 313 (1980) pp. 330-337. Lombard, J., et al. The brain wellness plan. Kensington Pub. Corp., 1998. Flesch M., et al., Effects of red and white wine on endothelium-dependent vasorelaxation of rat aorta and human coronary arteries. Am J Physiol 1998;275:1183-94. Fitzpatrick, D.F., Fleming R.C., Bing B, Maggi DA, O'Malley RM. Isolation and characterization of endothelium-dependent vasorelaxing compounds from grape seeds. J Agr & Food Chem In press. Fitzpatrick, D.F., Maggi D, Bing B, Coffey RG. Vasorelaxation, endothelium, and wine. BioFactors 1997;6:455-459. Fitzpatrick, D.F., Hirschfield SL, Ricci T, Jantzen P, Coffey RG. Endothelium-dependent vasorelaxation caused by various plant extracts. J Cardiovasc Pharmacol 1995;26:90-95. Fitzpatrick, D.F., Hirschfield SL, Coffey RG. Endothelium-dependent vasorelaxing activity of wine and other grape products. Amer J Physiol 1993;265:H774-H778. Lincoln, J., Hoyle, C.H.V., Burnstock, G., Nitric oxide in health and disease. Cambridge University Press, 1997. Facino, R.M., et al. Free radical scavenging action and anti-enzyme activities of procyanidines from vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994. Kuttan, R., Donnelly, P.V., Di Ferrante, N. Collagen treated with catechin becomes resistant to the action of mammalian collagenase. Experientia, 37: 221-223, 1981. Masquelier, J. Procyanidolic oligomers. J Parums Cosm Arom, 95: 89-97, 1990. Tixier, J.M., et al. Evidence by in vivo and in vitro studies that binding of [pyc] to elastin affects its rate of degradation by elastases. Biochem Pharmacol, 33: 3933-3939, 1984. Kakegawa, H., et al. Chem. Pharm. Bull. 33:5079, 1985. Harmand, M.F., Blanquet, P. The fate of total flavanolic oligomers extracted from ‘vitus vinifera l.’ in the rat. European Journal of Drug Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30. Delrieu, P., Ding J., Escande, B., Samain, D. Free-radical scavenging activity of proanthocyanidolic oligomers encapsulated in glycospheres: an in vivo and in vitro study. Cosmetology Department & S Biovectors, Ramonville St. Agne France. pp. 1-9. Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i converting enzyme by flavanolic compounds: in vitro and in vivo studies. Planta Medica, May 26, 1986. pp. 12-15. Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques chez l’animal-oedenme de la patte. Sanofi Res Toul Cedex Fr, pp31-40. Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques chez l’animal-activite aniagoniste vis-a-vis des mediateurs de l’inflamation. Sanofi Res Toul Cedex Fr, pp. 31-40. Dubos, C., Durst, G., Hugonot, H. Evolution de la resistance capillaire, spontanement ou artificiellement diminuee par l’action d’une substance capillaro-toxique chez des personnes agees--action benefique d’un agnet actif sur la micro-circulation: l’Endotelon. Inform. Therapeut. 1980. pp. 302-305. Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude d’un microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7, 1990. Lagrue, G., Olivier-Martin, F., Grillot, A. “Etude des effets des oligomeres du procyanidol sur las resistance capillaire dand l’hypertension arterielle et certaines nephropathies.” Sen. Hosp. Paris 18-25 Septembre, 1981. Beylot, C., Bioulac, P. Essai therapeutique d’un angioprotecteur peripherique, l’Endotelon. Actualite Therapeutique Gaz. Med. de France (87)22:2919-24, 1980. Lesbre, F.X., Tigaud, J.D. Effect de l’Endotelon sur l’indice de fragilite capillaire dan une population specifique: les sujets cirrhotiques. Gaz. Med. de France, (90)24 1983. Sarrat, L. Abord therapeutique des troubles fonctionnels des membres inferieurs par un microangioprotecteur l’Endotelon. Bordeaux Med, 11:685-8, 1981. Delacroix, P. Etude en double aveugle de l’Endotelon dans l’insuffisance veineuse chronique. Therapeutique, la Revue de Medicine, (27-28) Sept. 1981. pp. 1793-1802. Thebaut, J.F, Thebaut, P., Vin, F. Etude de l’Endotelon dand les manifestations fonctionnelles de l’insuffisance veineuse peripherique-resultats d’une etude en double aveugle portant sur 92 patients.” Gazette Medicale, (92)1, 1985. pp. 96-100. Masquelier, J. [pyc]: recent advances in the therapeutical activity of procyanidins. Supplement of Planta Medica, Journal of Medicinal Plant Research and Journal of Natural Products, July 1980 pp. 243-256. Henning, B., et al. Lipid peroxidation and endothelial cell injury: implications in atherosclerosis. Free Rad Path & Med, (4)1988 pp. 99-106. Masquelier, J. “Les procyanidols du vin leur role dans l’alcoolisme.” pp. 88-93. Gazave, J.M. “Notions recentes sur les capillaires” unpub. bulletin from the Laboratoire De Physiologie Patholigie pp. 26-29. Ruf, J.C. Wine and polyphenols related to platelet aggregation and atherothrombosis. Office International Vigne et du Vin, Nutrition and Health Unit, Paris France; Drugs under Experimental and Clinical Research (Switz.) 25/2-3 (125-131), 1999. Blaszo, G. Gabor, M. Oedema-inhibiting effect of procyanidin. Acta Physiologica Academiae Scientiarum Hungaricae, Tomus 56(2):235-240, 1980. Tayau, M.F, LeFevre, G. Action du leucocyanidol sur l’hyalaluronidase. Bull Soc Pharm Bordeaux, 95:132-136, 1956. Lamy, M. Utilization des oligomeres procyanidoliques en gynecologie. Essai Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22. Henriet, J.P “Une Etude Exemplaire Pour Un Phlebotrope: l’etude EIVE.’ Unpub., pp. 77-83. Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres procyanidoliques dans la paroi des capillaires sanguins du poumon decobaye. Acta Therapeutica (8) 1982. pp. 223-237. Kuttan, R., Donnelly, P., Di Ferrante, N. “Collagen treated with (+) -catechin becomes resistant to the action of mammalian collagenase.” Laboratory of Connective Tissue Research, Dept. of Biochem. Baylor Col. of Med., Houston TX. 28, May, 1980. Gendre, P., Laparra, J., Barraud, E. “Effect protecteur des oligomeres procyanidoliques sur le lathyrisme experimental chez le rat.” Ann. Pharm. Francaises, (43)1, 1985 pp. 61-73. Corbe, C., Boissin, J.P., Siou, A. Light vision and chorioretinal circulation. Study of the effect of procyanidolic oligomer (Endotelon). Jn. Fr. Opthalmol, (11)5:453-460, 1988. Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation and dazzling: use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol Fr, 88(2):173-4, 177-9, 1988. Proto, F. et al. Electrophysical study of vitis vinifera procyanoside oligomers effects on retinal function in myopic subjects. Ann Ott Clin Ocul, 114:85-93, 1988. Saracco, J.B., Estachy, G.M. Etude d l’Endotelon en opthalmologie. Gaz Med de France, 88:2035-2038, 1981. Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies. Klin Monatsbl Augenheilkd, 178:386-389, 1981. Corbe, C., et al. Microangiopathy of the retina. J. Fr. Opthalmol, 11:453, 1988. Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies et O.P.C. Bordeaux Medicale, (16)11. pp. 1467-74, 1978. Soyeux, A. et al. Endotelon. Diabetic retinopathy and hemorheology. Bull Soc Ophtalmol Fr. 87(12):1441-4, 1987. Fromantin, M. “Les oligomeres procyanidoliques dans le traitement de la fragilite capillaire et de la retinopathie chez les diabetiques. A propos de 26 cas.” Med Int, 16(11):432-434, Nov. 1981. Arne, J.L. Contribution a l’etude des oligomeres procyanidoliques: Endotelon, dans la retinopathie diabetique (a propos de 30 observations). Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982. Baruch, J. Effect of Endotelon in postoperative edema. Results of a double-blind study versus placebo in 32 female patients. Ann Chir Plast Esthet 29(4):393-5, 1984. Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism in rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62, 1981. Gabor, M. Pharmacologic effects of flavonoids on blood vessels. Angiologica, 9:355-374, 1972. Havsteen, B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol, 32:1141-48, 1983. Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer, H.J. Berkhauser Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger., 1977. Masquelier, J. Action protectrice du vin sur l’ulcere gastrique. Resultats, p. 61. Amella, M., et al. Inhibition of mast cell histamine release by flavonoids and bioflavonoids. Planta Medica, 5116-20, 1985. Packer, L., et al. The antioxidant miracle: your complete plan. John Wiley & Sons, Inc., 1999. Shaw, R. How [Australian] [pyc] [MASQUELIER’s®] Helps Sports People. Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums Cosmet Arom 95:89-97, 1990. Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques (Endotelon) dans le traitement des lymphoedemes post-therepeutiques de members superieurs. Symposium Satellite, Congres International d’Angiologie, Toulouse, France, 4-7 Oct. 1989. Fahey, T.D., Pearl M. Hormonal effects of phosphatidylserine during 2 weeks of intense training. Abstract submitted to national meeting of the Amer College of Sports Medicine, June 1998. Monteleone, P., Maj, M., Beinat, L., Natale, M., Kemali, D. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharm 43: 385–388, 1992. Fahey, T.D., et al. The hormonal and perceptive effects of phosphatidylserine administration during two weeks of resistive exercise-induced overtraining. Bio of Sport 15(3):135-44, 1998. Laparra, J., Michaud, J. Masquelier, J. Action des oligomeres procyanidoliques sur le cobaye carence en vitamin c. Tavaux Originaux, University of Bordeaux, 1976. Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’oxydation de l’acide ascorbique par les ions cuivriques. Bull. de la Societe de Chimie Biologique XXXIII (3-4) 1951. pp. 302-304. Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’acide ascorbique-oxydase. Bull. de la Societe de Chimie Biologique XXXIII (3,4) 1951. pp.304-306 Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T., Nonaka, G., Mishioka, I. “Inhibitory effects of tannins on hyaluronidase activation and on the degranulation from rat mesentery mast cells.” Chem. Pharm. Bull. 33(11)1985. 5079-5082. Reiman, H.J., Lorenz, M., Fischer, R., Frolich, H., Meyer, J. “Histamine and acute haemorrhagic lesions in rat gastric mucosa: prevention of stress ulcer formulation by (+)-catechin, an inhibitor of specific histidine decarboxylase in vitro.” Dirkhauser Verlag,Vol. 7/1, 1977. Pariente, J.J. Parientl-Amsellem, J. “Les oedemes post-traumatoqies chez le sportif: essai controle de l’Endothelon.” Actualite Therapeutique 90(3) 2/11 1983 pp. 231-235. Masquelier, J., et al. “Flavonoids et [pyc]” Int J Vit Nut Res, (49)3:307-311, 1979. Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem. Toxicol. 25(2):135-9, 1987. Pantaleoni, G.C., Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica Report, 1971. Laparra, J., et al., Acta Therapeutica, 4:233, 1978. Volkner, Wolfgang Muller, Ewald, Micronucleus assay in bone marrow cells of the mouse with [pyc]. Cytotest Cell Research GmbH & Co., projects 143010 & 143021; Feb. 1989. Acute and chronic toxicity tests. International Bio-Research, Inc., Hanover, Germany, 1967-1971. Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content in vegetable extracts to be used in the preparation of medicines. Bull. Soc. Pharm. Bordeaux, 129:51-65, 1990.
Contact Us | BUY NOW